CAR-T Cells Targeting Immune Checkpoint Pathway Players

Front Biosci (Landmark Ed). 2022 Apr 2;27(4):121. doi: 10.31083/j.fbl2704121.

Abstract

CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.

Trial registration: ClinicalTrials.gov NCT04213469 NCT04213469 NCT04185038 NCT04670068 NCT05241392 NCT04077866 NCT04662294.

Keywords: CAR-T cell; checkpoint; immunotherapy; review; tumor.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunotherapy
  • Immunotherapy, Adoptive
  • Neoplasms* / metabolism
  • Signal Transduction
  • T-Lymphocytes

Associated data

  • ClinicalTrials.gov/NCT04213469
  • ClinicalTrials.gov/NCT04213469
  • ClinicalTrials.gov/NCT04185038
  • ClinicalTrials.gov/NCT04670068
  • ClinicalTrials.gov/NCT05241392
  • ClinicalTrials.gov/NCT04077866
  • ClinicalTrials.gov/NCT04662294